La vendita allo scoperto per Xencor dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Xencor. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Xencor (NASDAQ:XNCR) Azioni, Report sulle vendite allo scoperto

Xencor

Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

Xencor Inc

<p>BMO Capital  analyst Etzer Darout   reiterates Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Outperform and raises the price target from $32 to $34.</p>


News

Price Target

Reiteration

Analyst Ratings

XNCR

BMO Capital Reiterates Outperform on Xencor, Raises Price Target to $34

<p>JP Morgan  analyst Brian Cheng   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Overweight and raises the price target from $27 to $28.</p>


JP Morgan Maintains Overweight on Xencor, Raises Price Target to $28

<p>Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.96) by 26.04 percent. This is a 77.5 percent decrease over losses of $(0.40) per share from the same period last year.  The company reported quarterly sales of $10.71 million which missed the analyst consensus estimate of $13.29 million by 19.41 percent.  This is a 81.90 percent decrease over sales of $59.16 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Xencor Q3 EPS $(0.71) Beats $(0.96) Estimate, Sales $10.71M Miss $13.29M Estimate

Biotech

General

Xencor Doses First The Subject In Its Phase 1/2 Study Of XmAb942

Xencor Presents Preclinical Data On XmAb942, A High-Potency Anti-TL1A Antibody For Inflammatory Bowel Diseases; Phase 1 Study In Healthy Volunteers Set To Begin In Q4 2024, With Initial Data Expected In First Half Of 2025

<p>Analysts' ratings for Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $31.0, a high estimate of $34.00, and a low estimate of $27.00. The current average, unchanged from the previous average price target, holds steady. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727362885_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Xencor among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Xencor. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Xencor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Xencor's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Xencor's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XNCR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Xencor analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Xencor: A Closer Look</h2>
<p>Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.</p>
<h3>Xencor: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Xencor faced challenges, resulting in a decline of approximately <strong>-62.74%</strong> in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-388.93%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-11.21%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Xencor's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-7.71%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Xencor's debt-to-equity ratio is below the industry average at <strong>0.16</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Xencor Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

<p>RBC Capital  analyst Gregory Renza   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Outperform and raises the price target from $31 to $34.</p>


RBC Capital Maintains Outperform on Xencor, Raises Price Target to $34

WIIM

Xencor shares are trading higher. The company priced its $175 million offering of 6.635 million shares of its common stock at $18.00 per share.

<p>The company also announced the pricing of pre-funded warrants to purchase up to an aggregate of 3.08 million shares of common stock at a price to the public of&nbsp;$17.99&nbsp;per pre-funded warrant.</p>
<p>The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately&nbsp;$175 million.</p>
<p>Xencor currently intends to use the net proceeds from the offering for general corporate purposes, which may include research and development, capital expenditures, working capital and general and administrative expenses.</p>


Offerings

Xencor Reports Pricing Of Public Offering Of 6.635M Shares Of Its Common Stock At $18.00 Per Share

Xencor Announces Proposed Public Offering of Common Stock; Size Not Given

Xencor shares are trading higher after the company announced four new XmAb programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs.

<p>Xencor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced four new XmAb&#xAE; programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and XmAb808 (B7-H3 x CD28) in patients with advanced solid tumors.</p>


Xencor Expands Pipeline with New Autoimmune Therapies and Cancer Trial Updates

<p>BMO Capital  analyst Etzer Darout   reiterates Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Outperform and maintains $32 price target.</p>


BMO Capital Reiterates Outperform on Xencor, Maintains $32 Price Target

<p>RBC Capital  analyst Gregory Renza   reiterates Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Outperform and maintains $31 price target.</p>


RBC Capital Reiterates Outperform on Xencor, Maintains $31 Price Target

<p>Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.88) by 21.59 percent. This is a 189.19 percent decrease over losses of $(0.37) per share from the same period last year.  The company reported quarterly sales of $16.96 million which beat the analyst consensus estimate of $15.83 million by 7.12 percent.  This is a 62.74 percent decrease over sales of $45.52 million the same period last year.</p>


Xencor Q2 EPS $(1.07) Misses $(0.88) Estimate, Sales $16.96M Beat $15.83M Estimate

<p>Across the recent three months, 5 analysts have shared their insights on Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $33.2, a high estimate of $40.00, and a low estimate of $27.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 11.7%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722452475_0_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Xencor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Sean McCutcheon</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$40.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xencor. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Xencor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Xencor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Xencor's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XNCR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Xencor analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Xencor</h2>
<p>Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.</p>
<h3>Xencor: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Xencor faced challenges, resulting in a decline of approximately <strong>-32.47%</strong> in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Xencor's net margin excels beyond industry benchmarks, reaching <strong>-531.3%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Xencor's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-10.62%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-7.41%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.15</strong>, Xencor adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 5 Analyst Evaluations For Xencor

<p>JP Morgan  analyst Brian Cheng   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Overweight and lowers the price target from $30 to $27.</p>


JP Morgan Maintains Overweight on Xencor, Lowers Price Target to $27

<p>In the latest quarter, 5 analysts provided ratings for Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $35.4, a high estimate of $40.00, and a low estimate of $31.00. A decline of 17.29% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1718388028_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A clear picture of Xencor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean McCutcheon</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$40.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Kaveri Pohlman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$56.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Xencor. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Xencor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Xencor's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Xencor's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XNCR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Xencor analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Xencor</h2>
<p>Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.</p>
<h3>Xencor: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Xencor's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately <strong>-32.47%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Xencor's net margin is impressive, surpassing industry averages. With a net margin of <strong>-531.3%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Xencor's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-10.62%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Xencor's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-7.41%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Xencor's debt-to-equity ratio is below the industry average. With a ratio of <b>0.15</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring Xencor Through Analyst Insights

<p>Raymond James  analyst Sean McCutcheon   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Strong Buy and lowers the price target from $58 to $40.</p>


Raymond James Maintains Strong Buy on Xencor, Lowers Price Target to $40

<p>BMO Capital  analyst Etzer Darout   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Outperform and lowers the price target from $34 to $32.</p>


BMO Capital Maintains Outperform on Xencor, Lowers Price Target to $32

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Xencor (XNCR – Research Report), with a price target of $34.0...

Xencor (XNCR) Gets a Buy from RBC Capital

Xencor ( ($XNCR) ) just unveiled an announcement. Dagmar Rosa-Bjorkeson will not seek reelection to the Xencor, Inc. Board of Directors in the 2025...

Xencor Board Member Dagmar Rosa-Bjorkeson to Step Down

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xencor (XNCR – Research Report), Argenica Therapeutics Ltd (AU:AG...

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), Argenica Therapeutics Ltd (AU:AGN) and Bio-Rad Laboratories (BIO)

Xencor (XNCR) announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb942, an investigational high-potency ...

Xencor doses first subject in first-in-human study of XmAb942

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Xencor (XNCR – Research Report), with a price target of $...

Xencor's Promising Advancements and Strategic Developments Justify Buy Rating

TD Cowen analyst Tara Bancroft has maintained their bullish stance on XNCR stock, giving a Buy rating yesterday. Tara Bancroft has given her Buy ra...

Xencor's Strategic Advancements and Promising Pipeline Drive Buy Rating

Xencor GAAP EPS of -$0.71 beats by $0.30, revenue of $10.71M misses by $2.62M

In a report released today, Peter Lawson from Barclays maintained a Sell rating on Xencor (XNCR – Research Report), with a price target of $22.00. ...

Barclays Sticks to Its Sell Rating for Xencor (XNCR)

Xencor Inc. ( ($XNCR) ) has released its Q3 earnings. Here is a breakdown of the information Xencor Inc. presented to its investors. Xencor, Inc. i...

Xencor Reports Q3 2024 Earnings and Program Updates

Xencor: Plamotamab NHL Data Leads To RA Program Advancement

Press Releases

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Xencor Announces Proposed Public Offering of Common Stock

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Xencor Announces Upcoming Change to Board of Directors

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Comments

Xencor

Vendite allo scoperto

Xencor (NASDAQ:XNCR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO